Minerva Neurosciences, Inc.

What they do

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, primarily schizophrenia. Its lead product candidate, roluperidone, is in a global confirmatory Phase 3 trial (C19) targeting negative symptoms of schizophrenia, a condition for which no approved treatment exists. The company has no commercial products and has not generated any revenue from product sales, reporting zero annual revenue from 2020 through 2024.

Revenue drivers

• No product revenue — The company has reported zero annual revenue for every year from 2020 through 2024, and all recent quarters also show zero revenue; it is pre-commercial with no approved products.
• Roluperidone (MIN-101C19) — The sole pipeline asset; a confirmatory Phase 3 trial is ongoing, with topline efficacy data expected in 2H 2027, but no revenue will be generated until regulatory approval and commercialization, which are uncertain.
• No other disclosed revenue streams — The company has not disclosed any licensing, collaboration, or partnership revenue; its only reported revenue event was a one-time $41.2M in Q2 2020, which is not recurring.

Recent performance

In the second quarter of 2026, Minerva reported R&D expense of $7.2 million, up from $1.3 million in the same period of 2025, reflecting increased activity in the C19 trial. Six-month R&D expense was $12.4 million in 2026 versus $2.7 million in 2025. The company reported a net loss of $293.4 million for fiscal 2025 (diluted EPS -$34.67), following a net income of $1.4 million in 2024. As of June 30, 2026, cash and equivalents stood at $24.7 million, with total assets of $95.1 million and total liabilities of $296.6 million, resulting in negative shareholder equity of $213.3 million.

Strategy

Management's stated priority is the execution of the C19 confirmatory Phase 3 trial of roluperidone, designed to confirm prior efficacy in negative symptoms of schizophrenia. The trial includes Phase A evaluating roluperidone 64 mg versus placebo at 12 weeks, and Phase B assessing relapse of positive symptoms over an additional 52-week period. The company has established a Scientific Advisory Board of 11 experts in psychiatry and neuroscience to guide the trial and future pipeline programs. Management also emphasizes thought leadership through publications in schizophrenia research, including a CATIE trial analysis.

Risks

• Clinical trial failure — The C19 trial may fail to confirm efficacy, which would likely end the development of roluperidone, the company's only product candidate.
• Capital depletion — With only $24.7 million in cash and negative equity of $213.3 million, the company requires substantial additional capital to fund the ongoing trial and operations, which may not be available.
• Regulatory and commercialization uncertainty — Even if the trial succeeds, FDA approval and commercial launch are not guaranteed, and no revenue has been generated to date.
• Dilution and financing risk — Raising capital through equity issuance would dilute existing shareholders; debt or licensing deals may impose restrictive covenants.

Outlook

Management expects topline efficacy data from Phase A of the C19 study in the second half of 2027, with Phase B relapse data expected in the second half of 2028. The company says it remains on track for execution, but given its cash position, additional financing will be needed to reach these milestones.